[Licensing negotiation in progress]
[Invitation for Expression of Interest - Deadline: 18 February 2018]
We are inviting expressions of interest (EoI) for commercializing “Buffered Propranolol Sublingual Tablet for Treatment of Artrial Fibrilation” technology. The innovation is developed by Professor CHOW Sing Sum Moses, of School of Pharmacy of The Chinese University of Hong Kong (CUHK Reference: 04/MED/176).
The Technology
The present invention features propranolol hydrochloride tablets suitable for sublingual administration to rapidly relief symptom of special artrial fibrillation. The tablet is prepared by mixing and direct compression of propranolol hydrochloride, buffering agent and other excipients into tablets. This composition could provide rapid disintergration and release of propranolol into the saliva in the oral cavity under the tongue to achieve rapid transfer of the propranolol into blood circulation, and thus quickly control chronic artrial fibrillation.
Commercialization
The technology is now available for licensing on an exclusive basis. In order to fully realize the benefit of the technology, we expect substantial investment is necessary to enable further research and development. In addition to the financial commitment, the licensee is expected to have the appropriate expertise as well as plans in marketing and strategizing the end product to ensure successful transfer of the technology to the society. Previous or existing business involvement and experience in this area is a plus.
This invitation of expression of interest is without prejudice. We also stress that this invitation is not a tender, and the University is not bound to accept any offer, or to accept the highest monetary offer, as there are additional considerations (such as the widest possible benefit to the community) that we, as a public institution, will need to take into consideration.
